CAMBREX CORP

Delisted

CIK 820081fmd_0MZVHPJBQ3H74P13JX6S8RADWMManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2009 to Sep 30, 2019, 39 periods

Income Statement · Annual · Millions · USD
Line item	FY2009	FY2010	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016	FY2017	FY2018
Total revenues	235	227	256	277	318	375	433	491	534	532
Cost of revenue	164	160	182	186	215	251	256	286	304	335
Net interest income	–	–	–	(2)	(2)	(2)	(2)	(1)	(1)	(4)
Gross profit	70	67	74	90	103	124	177	204	230	197
Research and development	8	10	11	10	10	13	13	14	17	16
Selling, general and administrative	36	34	39	45	48	52	58	58	69	69
Total operating expenses	–	–	50	55	58	66	86	74	86	95
Operating income	27	20	24	36	50	52	91	130	144	101
Interest expense	5	4	2	2	2	–	–	–	–	–
Other non-operating income (expense)	1	(1)	0	(0)	(0)	0	0	(2)	(1)	(1)
Income before taxes	–	15	20	31	45	46	90	128	142	110
Income tax expense	12	6	6	(32)	15	(13)	32	40	38	17
Net income from continuing operations	–	9	14	63	30	58	57	87	104	93
Net income	10	10	11	62	26	57	57	82	102	92